Review ArticleClinical Review

Managing Alzheimer Dementia Tomorrow

Thomas C. Rosenthal and Natan Khotianov
The Journal of the American Board of Family Practice September 2003, 16 (5) 423-434; DOI: https://doi.org/10.3122/jabfm.16.5.423

References

  1. ↵
    DeKosky ST, Orgogozo JM. Alzheimer disease: diagnosis, costs, and dimensions of treatment. Alzheimer Dis Assoc Disord 2001; 15 Suppl 1: S3–7.
  2. Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001; 285: 739–47.
    OpenUrlCrossRefPubMedWeb of Science
  3. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262: 2551–6.
    OpenUrlCrossRefPubMedWeb of Science
  4. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Annu Rev Public Health 2002; 23: 213–31.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Unverzagt FW, Gao S, Baiyewu O, et al. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology 2001; 57: 1655–62.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Scorer CA. Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer’s disease. Drug Discov Today 2001; 6: 1207–19.
    OpenUrlPubMed
  7. ↵
    Olson RE, Copeland RA, Seiffert D. Progress towards testing the amyloid hypothesis: inhibitors of APP processing. Curr Opin Drug Discov Devel 2001; 4: 390–401.
    OpenUrlPubMed
  8. ↵
    Selkoe DJ. The genetics and molecular pathology of Alzheimer’s disease: roles of amyloid and the presenilins. Neurol Clin 2000; 18: 903–22.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Jhee S, Shiovitz T, Crawford AW, Cutler NR. Beta-amyloid therapies in Alzheimer’s disease. Expert Opin Investig Drugs 2001; 10: 593–605.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Arch Med Res 2001; 32: 367–81.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Esler WP, Wolfe MS. A portrait of Alzheimer secretases–new features and familiar faces. Science 2001; 293: 1449–54.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, Stern D. Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim Biophys Acta 2000; 1502: 145–57.
    OpenUrlPubMed
  13. ↵
    Hensley K, Butterfield DA, Hall N, et al. Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer’s disease-associated amyloid beta peptide. Ann NY Acad Sci 1996; 786: 120–34.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–51.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Chorsky RL, Yaghmai F, Hill WD, Stopa EG. Alzheimer’s disease: a review concerning immune response and microischemia. Med Hypotheses 2001; 56: 124–7.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Blass JP. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001; 66: 851–6.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer’s disease: population based study. BMJ 1994; 309: 636–8.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Saunders AM, Trowers MK, Shimkets RA, et al. The role of apolipoprotein E in Alzheimer’s disease: pharmacogenomic target selection. Biochim Biophys Acta 2000; 1502: 85–94.
    OpenUrlPubMed
  19. ↵
    Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002; 346: 476–83.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Cummings JL, Vinters HV, Cole GM, et al. Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998; 51(1 Suppl 1): S2–17; discussion S65–7.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137–47.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    in t’ Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001; 345: 1515–21.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Retz W, Thome J, Durany N, et al. Potential genetic markers of sporadic Alzheimer’s dementia. Psychiatr Genet 2001; 11: 115–22.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Athan ES, Williamson J, Ciappa A, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 2001; 286: 2257–63.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741–66.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study [published erratum appears in Neurology 2000;55:161–2]. Neurology 1999; 53: 321–31.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Tanzi RE, Bertram L. New frontiers in Alzheimer’s disease genetics. Neuron 2001; 32: 181–4.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Brayne C, Harrington CR, Wischik CM, et al. Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia 1996; 7: 169–74.
  29. ↵
    Liddell MB, Lovestone S, Owen MJ. Genetic risk of Alzheimer’s disease: advising relatives. Br J Psychiatry 2001; 178: 7–11.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001; 58: 1828–31.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Weisen SF, Frishman WH, Aronson MK, Wassertheil-Smoller S. Self-rated health assessment and development of both cardiovascular and dementing illnesses in an ambulatory elderly population: a report from the Bronx Longitudinal Aging Study. Heart Dis 1999; 1: 201–5.
    OpenUrlPubMed
  32. ↵
    Wolf H, Grunwald M, Ecke GM, et al. The prognosis of mild cognitive impairment in the elderly. J Neural Transm Suppl 1998; 54: 31–50.
    OpenUrlPubMed
  33. ↵
    Camicioli R, Howieson D, Oken B, Sexton G, Kaye J. Motor slowing precedes cognitive impairment in the oldest old. Neurology 1998; 50: 1496–8.
  34. Andel R, Gatz M, Pedersen NL, Reynolds CA, Johansson B, Berg S. Deficits in controlled processing may predict dementia: a twin study. J Gerontol B Psychol Sci Soc Sci 2001; 56: P347–55.
    OpenUrlAbstract/FREE Full Text
  35. Woodruff-Pak DS. Eyeblink classical conditioning differentiates normal aging from Alzheimer’s disease. Integr Physiol Behav Sci 2001; 36: 87–108.
    OpenUrlPubMedWeb of Science
  36. ↵
    Linn RT, Wolf PA, Bachman DL, et al. The ‘preclinical phase’ of probable Alzheimer’s disease. A 13-year prospective study of the Framingham cohort. Arch Neurol 1995; 52: 485–90.
    OpenUrlCrossRefPubMedWeb of Science
  37. Howieson DB, Dame A, Camicioli R, Sexton G, Payami H, Kaye JA. Cognitive markers preceding Alzheimer’s dementia in the healthy oldest old. J Am Geriatr Soc 1997; 45: 584–9.
    OpenUrlPubMedWeb of Science
  38. Derrer DS, Howieson DB, Mueller EA, Camicioli RM, Sexton G, Kaye JA. Memory testing in dementia: how much is enough? J Geriatr Psychiatry Neurol 2001; 14: 1–6.
    OpenUrlAbstract/FREE Full Text
  39. Halpern AR, O’Connor MG. Implicit memory for music in Alzheimer’s disease. Neuropsychology 2000; 14: 391–7.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48: 314–8.
    OpenUrlPubMedWeb of Science
  41. ↵
    Argyriadou S, Vlachonikolis I, Melisopoulou H, Katachanakis K, Lionis C. In what extent anemia coexists with cognitive impairment in elderly: a cross-sectional study in Greece. BMC Fam Pract 2001; 2: 5.
    OpenUrlCrossRefPubMed
  42. ↵
    Hogervorst E, Combrinck M, Lapuerta P, Rue J, Swales K, Budge M. The Hopkins Verbal Learning Test and screening for dementia. Dement Geriatr Cogn Disord 2002; 13: 13–20.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    Sunderland T, Hill JL, Mellow AM, et al. Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc 1989; 37: 725–9.
    OpenUrlPubMedWeb of Science
  44. ↵
    Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 2000; 15: 548–61.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    Flicker L, Logiudice D, Carlin JB, Ames D. The predictive value of dementia screening instruments in clinical populations. Int J Geriatr Psychiatry 1997; 12: 203–9.
    OpenUrlCrossRefPubMedWeb of Science
  46. O’Connor DW, Pollitt PA, Roth M, Brook PB, Reiss BB. Memory complaints and impairment in normal, depressed, and demented elderly persons identified in a community survey. Arch Gen Psychiatry 1990; 47: 224–7.
    OpenUrlCrossRefPubMedWeb of Science
  47. O’Connor DW, Pollitt PA, Treasure FP, Brook CP, Reiss BB. The influence of education, social class and sex on Mini-Mental State scores. Psychol Med 1989; 19: 771–6.
    OpenUrlPubMedWeb of Science
  48. ↵
    Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc 1993; 41: 1029–32.
    OpenUrlPubMedWeb of Science
  49. ↵
    Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2001; 56: 1133–42.
    OpenUrl
  50. ↵
    Chui H, Zhang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology’s practice parameters. Neurology 1997; 49: 925–35.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Massoud F, Devi G, Moroney JT, et al. The role of routine laboratory studies and neuroimaging in the diagnosis of dementia: a clinicopathological study. J Am Geriatr Soc 2000; 48: 1204–10.
    OpenUrlPubMedWeb of Science
  52. ↵
    Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143–53.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Beck FK, Rosenthal TC. Prealbumin: a marker for nutritional evaluation. Am Fam Physician 2002; 65: 1575–8.
    OpenUrlPubMedWeb of Science
  54. ↵
    Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer’s disease. Brain Res Bull 2001; 54: 565–8.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    Myagkova MA, Gavrilova SI, Lermontova NN, et al. Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer’s disease and senile dementia of the Alzheimer type. Bull Exp Biol Med 2001; 131: 127–9.
    OpenUrlCrossRefPubMed
  56. ↵
    Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57: 801–5.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Yamada T, Tsujioka Y, Taguchi J, et al. Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer’s disease. Brain Res 1999; 845: 1–5.
    OpenUrlCrossRefPubMed
  58. ↵
    Sjogren M, Blomberg M, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001; 66: 510–6.
    OpenUrlCrossRefPubMed
  59. ↵
    Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type. Neurology 2001; 57: 1763–6.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52: 1397–403.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiol Aging 2001; 22: 747–54.
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    Camicioli R, Moore MM, Sexton G, Howieson DB, Kaye JA. Age-related brain changes associated with motor function in healthy older people. J Am Geriatr Soc 1999; 47: 330–4.
    OpenUrlPubMedWeb of Science
  63. Sencakova D, Graff-Radford NR, Willis FB, et al. Hippocampal atrophy correlates with clinical features of Alzheimer disease in African Americans. Arch Neurol 2001; 58: 1593–7.
    OpenUrlCrossRefPubMedWeb of Science
  64. Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997; 48: 1297–304.
    OpenUrlAbstract/FREE Full Text
  65. Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001; 57: 1756–63.
    OpenUrlAbstract/FREE Full Text
  66. Mueller EA, Moore MM, Kerr DC, et al. Brain volume preserved in healthy elderly through the eleventh decade. Neurology 1998; 51: 1555–62.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 24–35.
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 286: 2120–7.
    OpenUrlCrossRefPubMedWeb of Science
  69. ↵
    Olafsdottir M, Foldevi M, Marcusson J. Dementia in primary care: why the low detection rate? Scand J Prim Health Care 2001; 19: 194–8.
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154–66.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    Peters R. The prevention of dementia. J Cardiovasc Risk 2001; 8: 253–6.
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    Stern Y, Moeller JR, Anderson KE, et al. Different brain networks mediate task performance in normal aging and AD: defining compensation. Neurology 2000; 55: 1291–7.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999; 341: 1670–9.
    OpenUrlCrossRefPubMedWeb of Science
  74. ↵
    O’Brien JT, Ballard CG. Drugs for Alzheimer’s disease. BMJ 2001; 323: 123–4.
    OpenUrlFREE Full Text
  75. ↵
    Irizarry MC, Hyman BT. Alzheimer disease therapeutics. J Neuropathol Exp Neurol 2001; 60: 923–8.
    OpenUrlPubMedWeb of Science
  76. ↵
    Dominguez DI, De Strooper B, Annaert W. Secretases as therapeutic targets for the treatment of Alzheimer’s disease. Amyloid 2001; 8: 124–42.
    OpenUrlPubMed
  77. ↵
    Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–7.
    OpenUrlCrossRefPubMedWeb of Science
  78. Younkin SG. Amyloid beta vaccination: reduced plaques and improved cognition. Nat Med 2001; 7: 18–9.
    OpenUrlCrossRefPubMedWeb of Science
  79. Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann Neurol 2000; 48: 567–79.
    OpenUrlCrossRefPubMedWeb of Science
  80. ↵
    Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336: 1216–22.
    OpenUrlCrossRefPubMedWeb of Science
  81. ↵
    Brodaty H, Ames D, Boundy KL, et al. Pharmacological treatment of cognitive deficits in Alzheimer’s disease. Med J Aust 2001; 175: 324–9.
    OpenUrlPubMed
  82. ↵
    Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 121–6.
    OpenUrlPubMedWeb of Science
  83. ↵
    Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001; (4): CD003159.
    OpenUrl
  84. ↵
    Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991; 78: 991–5.
    OpenUrlPubMedWeb of Science
  85. ↵
    Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study [published erratum appears in JAMA 2000;284:2597]. JAMA 2000; 283: 1007–15.
    OpenUrlCrossRefPubMedWeb of Science
  86. ↵
    Shumaker SA, Legault C, Thai L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651–62.
    OpenUrlCrossRefPubMedWeb of Science
  87. ↵
    LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285: 1489–99.
    OpenUrlCrossRefPubMedWeb of Science
  88. ↵
    Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288: 2123–9.
    OpenUrlCrossRefPubMedWeb of Science
  89. ↵
    Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48: 626–32.
    OpenUrlAbstract/FREE Full Text
  90. ↵
    Zandi PP, Breitner JC, Anthony JC. Is pharmacological prevention of Alzheimer’s a realistic goal? Exp Opin Pharmacother 2002; 3: 365–80.
    OpenUrlCrossRefPubMed
  91. ↵
    Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999; 282: 254–60.
    OpenUrlCrossRefPubMedWeb of Science
  92. ↵
    Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439–43.
    OpenUrlCrossRefPubMedWeb of Science
  93. ↵
    Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59: 378–84.
    OpenUrlCrossRefPubMedWeb of Science
  94. ↵
    Scott HD, Laake K. Statins for the prevention of Alzheimer’s disease. Cochrane Database Syst Rev 2001; (4): CD003160.
    OpenUrl
  95. ↵
    Wiebe S, Nicolle MW. Recent developments in neurology [published erratum appears in BMJ 2002;325:366]. BMJ 2002; 324: 656–60.
    OpenUrlFREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section